Does Sarepta Therapeutics Inc (SRPT) Stock have plenty of room for growth?
BMO Capital Markets raised the price target for the Sarepta Therapeutics Inc (NASDAQ:SRPT) stock to “an Outperform”. The rating was released on January 31, 2024, according to finviz. The research report from Deutsche Bank has initiated the stock to Buy, with a price target set at $109. The stock was initiated by Wedbush, who disclosed […]
Facts about Sarepta Therapeutics Inc (SRPT) Stock that you might not know
BMO Capital Markets raised the price target for the Sarepta Therapeutics Inc (NASDAQ:SRPT) stock to “an Outperform”. The rating was released on January 31, 2024, according to finviz. The research report from Deutsche Bank has initiated the stock to Buy, with a price target set at $109. The stock was initiated by Wedbush, who disclosed […]
What are the chances of Sarepta Therapeutics Inc (SRPT) Stock turning the corner?
BMO Capital Markets raised the price target for the Sarepta Therapeutics Inc (NASDAQ:SRPT) stock to “an Outperform”. The rating was released on January 31, 2024, according to finviz. The research report from Deutsche Bank has initiated the stock to Buy, with a price target set at $109. The stock was initiated by Wedbush, who disclosed […]
Hold on to your shares: Sarepta Therapeutics Inc (SRPT) Stock
BMO Capital Markets raised the price target for the Sarepta Therapeutics Inc (NASDAQ:SRPT) stock to “an Outperform”. The rating was released on January 31, 2024, according to finviz. The research report from Deutsche Bank has initiated the stock to Buy, with a price target set at $109. The stock was initiated by Wedbush, who disclosed […]
With upside potential, Sarepta Therapeutics Inc (SRPT) Stock is well-positioned to grow
BMO Capital Markets raised the price target for the Sarepta Therapeutics Inc (NASDAQ:SRPT) stock to “an Outperform”. The rating was released on January 31, 2024, according to finviz. The research report from Deutsche Bank has initiated the stock to Buy, with a price target set at $109. The stock was initiated by Wedbush, who disclosed […]
Are Options A Good Investment Right Now? Sarepta Therapeutics Inc (SRPT) Stock
BMO Capital Markets raised the price target for the Sarepta Therapeutics Inc (NASDAQ:SRPT) stock to “an Outperform”. The rating was released on January 31, 2024, according to finviz. The research report from Deutsche Bank has initiated the stock to Buy, with a price target set at $109. The stock was initiated by Wedbush, who disclosed […]